...
首页> 外文期刊>Biochemical Pharmacology >N(6)-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A(3) adenosine receptors.
【24h】

N(6)-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A(3) adenosine receptors.

机译:N(6)取代的腺苷衍生物:A(3)腺苷受体的选择性,功效和种类差异。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The activation of the human A(3) adenosine receptor (AR) by a wide range of N(6)-substituted adenosine derivatives was studied in intact CHO cells stably expressing this receptor. Selectivity of binding at rat and human ARs was also determined. Among N(6)-alkyl substitutions, small N(6)-alkyl groups were associated with selectivity for human A(3)ARs vs. rat A(3)ARs, and multiple points of branching were associated with decreased hA(3)AR efficacy. N(6)-Cycloalkyl-substituted adenosines were full (/=6 carbons) hA(3)AR agonists. N(6)-(endo-Norbornyl)adenosine 13 was the most selective for both rat and human A(1)ARs. Numerous N(6)-arylmethyl analogues, including substituted benzyl, tended to be more potent in binding to A(1) and A(3) vs. A(2A)ARs (with variable degrees of partial to full A(3)AR agonisms). A chloro substituent decreased the efficacy depending on its position on the benzyl ring. The A(3)AR affinity and efficacy of N(6)-arylethyl adenosines depended highly on stereochemistry, steric bulk, and ring constraints. Stereoselectivity of binding was demonstrated for N(6)-(R-1-phenylethyl)adenosine vs. N(6)-(S-1-phenylethyl)adenosine, as well as for the N(6)-(1-phenyl-2-pentyl)adenosine, at the rat, but not human A(3)AR. Interestingly, DPMA, a potent agonist for the A(2A)AR (K(i)=4nM), was demonstrated to be a moderately potent antagonist for the human A(3)AR (K(i)=106nM). N(6)-[(1S,2R)-2-Phenyl-1-cyclopropyl]adenosine 48 was 1100-fold more potent in binding to human (K(i)=0.63nM) than rat A(3)ARs. Dual acting A(1)/A(3) agonists (N(6)-3-chlorobenzyl- 29, N(6)-(S-1-phenylethyl)- 39, and 2-chloro-N(6)-(R-phenylisopropyl)adenosine 53) might be useful for cardioprotection.
机译:在稳定表达该受体的完整CHO细胞中研究了广泛的N(6)取代的腺苷衍生物对人A(3)腺苷受体(AR)的激活。还确定了在大鼠和人ARs上结合的选择性。在N(6)-烷基取代中,小的N(6)-烷基与人类A(3)AR与大鼠A(3)AR的选择性相关,并且多个分支点与hA(3)降低相关AR功效。 N(6)-环烷基取代的腺苷是完整的( / = 6个碳原子)hA(3)AR激动剂。 N(6)-(endo-Norbornyl)腺苷13对大鼠和人类A(1)ARs的选择性最高。相对于A(2A)AR,许多N(6)-芳基甲基类似物(包括取代的苄基)倾向于更有效地与A(1)和A(3)结合(部分或全部A(3)AR的程度不同激动剂)。氯取代基取决于其在苄基环上的位置而降低了功效。 N(6)-芳基乙基腺苷的A(3)AR亲和力和功效在很大程度上取决于立体化学,空间体积和环约束。证明了N(6)-(R-1-苯基乙基)腺苷与N(6)-(S-1-苯基乙基)腺苷以及N(6)-(1-苯基-)结合的立体选择性2-戊基)腺苷,在大鼠处,而非人A(3)AR。有趣的是,DPMA是A(2A)AR(K(i)= 4nM)的有效激动剂,被证明是人A(3)AR(K(i)= 106nM)的中效拮抗剂。 N(6)-[(1S,2R)-2-苯基-1-环丙基]腺苷48与大鼠(K(i)= 0.63nM)的结合力比大鼠A(3)AR高1100倍。双作用A(1)/ A(3)激动剂(N(6)-3-氯苄基-29,N(6)-(S-1-苯乙基)-39和2-氯-N(6)-( R-苯基异丙基)腺苷53)可能对心脏保护有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号